XFOR x4pharma.com: Forward Price-to-Revenue Multiple
Global political tensions are hindering international testing of immune therapies and disrupting component supply chains. This X4 Pharmaceuticals (XFOR) projected P/S chart clearly confirms the volatility of market expectations, where the parameter value equals 18.70. However, X4 Pharmaceuticals is developing the unique XOLREMDI to combat WHIM syndrome, and operating within the US legal framework minimizes sanction risks due to the humanitarian status of the developments.
Metric breakdowns and analytics for X4 Pharmaceuticals, Inc (XFOR)
- current price and projected stock value:
- company stock capitalization data:
- business book valuation details:
- company total debt and liquidity indicators:
Aggregate Debt to Equity X4 Pharmaceuticals|XFOR - Long-Term Debt to Capital|Ratio of Short-Term Indebtedness to Capital X4 Pharmaceuticals|XFOR - Company Aggregate Debts|Debts to Book Capitalization X4 Pharmaceuticals, Inc|XFOR - Company Long-Term Debt|Company Short-Term Loans and Borrowings X4 Pharmaceuticals|Quick Liquidity Indicator x4pharma.com
- earnings and multiples data:
XFOR - Net Profit|Projected Future Earnings X4 Pharmaceuticals|XFOR - P/E Multiple|Projected Price to Earnings X4 Pharma|XFOR - PEG Multiple|Company Value to EBITDA X4 Pharmaceuticals, Inc|XFOR - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) X4 Pharmaceuticals|XFOR - Net earnings per share for the last 12 months|Year-over-year earnings per share growth rate for the last twelve months x4pharma.com|XFOR - Earnings growth in current year|Consensus forecast of earnings per share growth for next year X4 Pharmaceuticals
- sales and revenue data:
Fundamental company analysis:X4 Pharmaceuticals, Inc. XFOR
For the R&D-intensive business of X4 Pharmaceuticals (XFOR), which focuses on rare immune pathologies, the forward P/S ratio serves as a gauge of market expectations for future commercial success. This metric correlates current market capitalization with projected revenue, reflecting the premium placed on the innovative potential of its team of onco-immunologists. By analyzing the dynamics of the expected P/S, an investor can assess the balance between leadership in clinical phases and the risks of failing to meet sales targets.
Who X4 Pharmaceuticals competes with
Forward P/S Multiple ARGX (argenx)|BioNTech Inc. (BNTX) - Market Cap to Future Revenue Ratio|ABVX: Forward Price-to-Revenue Multiple|ADMA (ADMA Corp) - Market Cap to Projected Revenue|Market Cap to Projected Revenue Protagonist Therapeutics|Forward Price-to-Revenue Multiple immunovant.com|KNSA - Forward Price to Sales|Price-to-Projected Revenue Ratio GRFS|ADPT - Future Price to Revenue|Forward P/S Multiple Celldex Corp (CLDX)|Forward Price to Sales Aurinia Pharmaceuticals|Forward P/S Multiple biocryst.com BCRX|Vera Therapeutics - Forward P/S Multiple|DNTH: Price-to-Projected Revenue Ratio|Forward Price to Sales Pharvaris Corp PHVS|ABCL (AbCellera Corp) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple TRML|Forward P/S Multiple precigen.com|Forward P/S Multiple PHAR|Forward P/S Multiple Nektar Therapeutics Inc (NKTR)|Upstream Bio Corp - Forward Price-to-Revenue Multiple|Forward P/S Multiple Zenas Corp ZBIO|IMNM (Immunome, Inc.) - Market Cap to Future Revenue Ratio|gossamerbio.com (GOSS) - Forward Price-to-Revenue Multiple|KALV: Forward P/S Multiple|Forward Price-to-Revenue Multiple Septerna, Inc.|Pieris Pharmaceuticals Inc (PVLA) - Price to Expected Revenue Ratio|Forward P/S Multiple Savara Pharma|RIGL (Rigel Pharmaceuticals) - Market Cap to Expected Sales Ratio|Forward P/S Multiple anaptysbio.com (ANAB)|Astria Therapeutics, Inc. - Forward Price-to-Revenue Multiple|Forward P/S Multiple enGene Holdings Inc ENGN|RAPT Therapeutics, Inc. - Forward P/S Multiple|JBIO: Price-to-Projected Revenue Ratio|Aclaris Therapeutics (ACRS) - Price-to-Projected Revenue Ratio|KYTX (kyvernatx.com) - Price-to-Projected Revenue Ratio|TLSA: Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple Cabaletta Bio Inc. (CABA)|Market Cap to Projected Revenue Ventyx Bio VTYX|Forward P/S Multiple Theratechnologies, Inc (THTX)|Avalo Therapeutics, Inc (AVTX) - Future Price to Revenue|eledon.com - Price-to-Projected Revenue Ratio|AGEN (Agenus Inc.) - Market Cap to Future Revenue Ratio|CLYM: Price-to-Projected Revenue Ratio|Forward Price to Sales Zura Bio Limited ZURA|ATYR (aTyr Pharmaceuticals) - Price-to-Projected Revenue Ratio|Future Price to Revenue Adagene Inc ADAG|Forward P/S Multiple Ikena Oncology, Inc.|Shattuck Labs, Inc. (STTK) - Forward Price to Sales|Forward P/S Multiple equilliumbio.com (EQ)|Forward P/S Multiple CNTB (Connect Biopharma Holdings Limited)|Immunic Therapeutics - Price-to-Projected Revenue Ratio|Forward Price to Sales Atara Biotherapeutics Inc (ATRA)|IFRX: Price-to-Projected Revenue Ratio|ACET (adicetbio.com) - Forward Price-to-Revenue Multiple|Celularity (CELU) - Forward P/S Multiple|INMB (INmune Bio Corp) - Forward P/S Multiple|Forward Price-to-Revenue Multiple Barinthus Biotherapeutics Corp (BRNS)|Kezar Life Sciences (KZR) - Forward Price to Sales|Forward P/S Multiple sabbiotherapeutics.com (SABS)|Market Cap to Expected Sales Ratio AKTX|Enlivex Therapeutics Ltd - Price-to-Projected Revenue Ratio|QTTB: Forward Price-to-Revenue Multiple|GOVX: Price-to-Projected Revenue Ratio|EDSA (Edesa Biotech, Inc.) - Forward Price-to-Revenue Multiple|Forward Price-to-Revenue Multiple ibioinc.com|CARM (Carisma Therapeutics Inc) - Forward P/S Multiple|Price-to-Projected Revenue Ratio XTLB|Market Cap to Projected Revenue Bolt Biotherapeutics BOLT|Forward P/S Multiple hcwbiologics.com (HCWB)|APVO: Market Cap to Future Revenue Ratio|AIM - Forward Price-to-Revenue Multiple|Aditxt Corp (ADTX) - Market Cap to Projected Revenue|GRI (GRI Bio Inc) - Market Cap to Projected Revenue|XRTX (XORTX) - Forward Price-to-Revenue Multiple|Vyome Therapeutics - Forward Price to Sales|Price-to-Projected Revenue Ratio Revelation Biosciences|indaptusrx.com - Future Price to Revenue|Forward P/S Multiple SCNI|CALI (calcimedica.com) - Forward Price to Sales|Forward P/S Multiple AFMD (Affimed N.V.)|Forward P/S Multiple Allakos Inc ALLK|HOOK - Price-to-Projected Revenue Ratio|Forward Price to Sales IGMS (IGM Biosciences, Inc.)|iTeos Therapeutics, Inc. (ITOS) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple Ocean Biomedical Inc|TCBP (TC BioPharm (Holdings) PLC) - Forward P/S Multiple|Forward P/S Multiple Third Harmonic Bio Inc
